[Recent progress in basic research concerning the management of benign prostatic hyperplasia].
New therapeutic targets in benign prostatic hyperplasia (BPH) mainly concern phosphodiesterase type 5 (PDE-5) inhibitors. The effects of PDE-5 inhibitors in the treatment of lower urinary tract symptoms (LUTS) related to BPH appear to be related to their pathophysiological action on detrusor and prostatic muscle cell contraction and relaxation. Several fundamental studies have been conducted to precisely investigate and describe the pharmacological mechanisms of PDE-5 inhibitors and have shown that they reduce the contraction of prostatic cells submitted to various types of contractile stimuli in vitro. These dose-dependent effects are increased in combination with an alpha1-blocker and may constitute an additional therapeutic solution for the treatment of LUTS in the near future.
Cornu
Jean-Nicolas
JN
Service d'Urologie de l'Hôpital Pitié-Salpêtrière, Paris, France.
Rouprêt
Morgan
M
D005576:Colforsin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009119:Muscle Contraction; D018482:Muscle, Skeletal / Q000503:physiopathology; D010656:Phenylephrine / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011687:Purines / Q000627:therapeutic use; D020889:Rolipram / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D005576:Colforsin; D010656:Phenylephrine; D000068677:Sildenafil Citrate; D020889:Rolipram